Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Lancet
Toyoaki HidaTomohide Tamura

Abstract

Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-positive non-small-cell lung cancer. Given those promising results, we did a phase 3 trial to directly compare the efficacy and safety of alectinib and crizotinib. J-ALEX was a randomised, open-label, phase 3 trial that recruited ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer, who were chemotherapy-naive or had received one previous chemotherapy regimen, from 41 study sites in Japan. Patients were randomly assigned (1:1) via an interactive web response system using a permuted-block method stratified by Eastern Cooperative Oncology Group performance status, treatment line, and disease stage to receive oral alectinib 300 mg twice daily or crizotinib 250 mg twice daily until progressive disease, unacceptable toxicity, death, or withdrawal. The primary endpoint was progression-free survival assessed by an independent review facility. The efficacy analysis was done in the intention-to-treat population, and safety analyses were done in all patients who received at least one dose of the stu...Continue Reading

Citations

Jun 29, 2017·Expert Review of Anticancer Therapy·Tania Losanno, Cesare Gridelli
Jun 6, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ross A SooDavid R Spigel
Feb 13, 2018·Pathology International·Tomoko DaiMasayuki Noguchi
Mar 2, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin Früh, Solange Peters
Sep 1, 2017·Nature Reviews. Clinical Oncology·Alison M SchramAlexander Drilon
Oct 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D UlahannanS-M Lee
Oct 5, 2017·Japanese Journal of Clinical Oncology·Masafumi SaikiMakoto Nishio
Apr 19, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S NovelloJ Wolf
Dec 19, 2017·Memo·Gudrun AbsengerAngelika Bezan
Dec 1, 2017·Expert Review of Anticancer Therapy·Assunta SgambatoCesare Gridelli
Apr 25, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M NagasakaS-H I Ou
Jul 11, 2018·Future Oncology·Claudio SiniAldo Pezzuto
Aug 2, 2018·Journal of Clinical Medicine·Kim Tam BuiMichael Boyer
Jan 10, 2018·The Journal of International Medical Research·Liping LinXiaolong Cao
Sep 28, 2018·Current Treatment Options in Neurology·Bicky ThapaManmeet S Ahluwalia
Oct 5, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PlanchardUNKNOWN ESMO Guidelines Committee
Sep 7, 2018·Advances in Anatomic Pathology·Yin P Hung, Lynette M Sholl
Sep 28, 2018·Expert Review of Anticancer Therapy·Radhamani Kannaiyan, Daruka Mahadevan
Nov 6, 2018·Current Opinion in Oncology·Christoph Oliver RyserOliver Gautschi
Dec 24, 2018·Expert Review of Anticancer Therapy·Yuka KozumaTakashi Seto
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Danilo RoccoCesare Gridelli
Jan 22, 2019·Nature Cell Biology·Qianting ZhangXin-Hua Feng
Feb 23, 2018·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ashley C LyMorgan B Smith
Jan 19, 2019·Expert Review of Clinical Pharmacology·Junyi Yang, Weiliang Gong
Feb 20, 2018·Molecular Cancer·Carminia Maria Della CorteFloriana Morgillo
Nov 17, 2017·European Respiratory Review : an Official Journal of the European Respiratory Society·Céline MascauxFabrice Barlesi
Mar 11, 2018·Surgical Case Reports·Naoko ImanishiFumihiro Tanaka
Jan 25, 2018·Nature·Roy S HerbstChris Boshoff
Mar 21, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T ShawJean-François Martini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.